[1] |
Henske EP, Jóźwiak S, Kingswood JC, et al. Tuberous sclerosis complex[J]. Nat Rev Dis Primers. 2016,2:16035. doi: 10.1038/nrdp.2016.35.
|
[2] |
Goldburg SR, Strober BE, Payette MJ. Hidradenitis suppurativa: epidemiology, clinical presentation, and pathogenesis[J]. J Am Acad Dermatol, 2020,82(5):1045⁃1058. doi: 10.1016/j.jaad.2019. 08.090.
|
[3] |
Richards S, Aziz N, Bale S, et al. Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology[J]. Genet Med, 2015,17(5):405⁃424. doi: 10.1038/gim.2015.30.
|
[4] |
Au KS, Williams AT, Roach ES, et al. Genotype/phenotype correlation in 325 individuals referred for a diagnosis of tuberous sclerosis complex in the United States[J]. Genet Med, 2007,9(2):88⁃100. doi: 10.1097/gim.0b013e31803068c7.
|
[5] |
Curatolo P, Moavero R, de Vries PJ. Neurological and neuropsy⁃chiatric aspects of tuberous sclerosis complex[J]. Lancet Neurol, 2015,14(7):733⁃745. doi: 10.1016/S1474⁃4422(15)00069⁃1.
|
[6] |
Sharma MC, Ralte AM, Gaekwad S, et al. Subependymal giant cell astrocytoma⁃⁃a clinicopathological study of 23 cases with special emphasis on histogenesis[J]. Pathol Oncol Res, 2004,10(4):219⁃224. doi: 10.1007/BF03033764.
|
[7] |
Li M, Zhou Y, Chen C, et al. Efficacy and safety of mTOR inhibitors (rapamycin and its analogues) for tuberous sclerosis complex: a meta⁃analysis[J]. Orphanet J Rare Dis, 2019,14(1):39. doi: 10.1186/s13023⁃019⁃1012⁃x.
|
[8] |
周鹏军, 王宝玺, 林立航, 等. γ分泌酶基因突变在反常性痤疮的研究进展[J]. 中华皮肤科杂志, 2019,52(9):656⁃659. doi:10.3760/cma.j.issn.0412⁃4030.2019.09.015.
|
[9] |
张晓峰, 苏惠春, 覃云飞, 等. 反常性痤疮一家系调查及致病基因突变分析[J]. 中华皮肤科杂志, 2016,49(7):508⁃510.
|
[10] |
Monfrecola G, Balato A, Caiazzo G, et al. Mammalian target of rapamycin, insulin resistance and hidradenitis suppurativa: a possible metabolic loop[J]. J Eur Acad Dermatol Venereol, 2016,30(9):1631⁃1633. doi: 10.1111/jdv.13233.
|
[11] |
Balato A, Caiazzo G, Annunziata MC, et al. Anti⁃TNF⁃α therapy modulates mTORC1 signalling in hidradenitis suppurativa[J]. J Eur Acad Dermatol Venereol, 2019,33(1):e43⁃e45. doi: 10.1111/ jdv.15160.
|
[12] |
De Vita V, Melnik BC. mTORC1 at the crossroad of metabolism and immunity in hidradenitis suppurativa[J]. J Eur Acad Dermatol Venereol, 2019,33(3):e107⁃e109. doi: 10.1111/jdv.15270.
|
[13] |
Ingram JR. The epidemiology of hidradenitis suppurativa[J]. Br J Dermatol, 2020,183(6):990⁃998. doi: 10.1111/bjd.19435.
|